Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen No Longer Exclusive Distributor of Blue Heron's Synthetic Genes

NEW YORK (GenomeWeb News) — Invitrogen said today it will now co-exclusively distribute Blue Heron Biotechnology’s custom synthesis genes worldwide, updating an alliance it penned last year that made it the exclusive distributor.
 
Terms of the revamped deal call for Invitrogen to continue to supply Blue Heron’s GeneMaker technology to its pharmaceutical and life sciences customers worldwide.
 
In the original agreement, disclosed in December 2006, Invitrogen said it made an undisclosed equity investment in Blue Heron in return for becoming its exclusive worldwide distributor. Invitrogen said at that time it was shifting away from its history as a provider of clones to becoming a synthetic gene provider.
 
Financial terms of the revamped agreement were not disclosed.
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.